[Imunofan: new-generation synthetic peptide agent]

Area of Science:

• Immunology
• Pharmacology
• Biochemistry

Background:

• Synthetic regulatory peptides are developed by modifying natural hormone fragments.
• New-generation peptides offer altered biological activity and therapeutic properties.
• Thymopoietin modification led to the development of the hexapeptide Immunofan.

Purpose of the Study:

• To review the development, mechanism of action, and applications of synthetic regulatory peptides.
• To evaluate the therapeutic potential of Immunofan in pathogenetic and immunocorrective therapy.
• To assess Immunofan's effects on immune function, inflammation, and oxidative stress.

Main Methods:

• Chemical modification of thymic hormone Thymopoietin (positions 32-37) to create Arg-alpha-Asp-Lys-Val-Tyr-Arg (Immunofan).
• Review of studies on Immunofan's efficacy in various disease models.
• Analysis of Immunofan's impact on cell immunity, neutrophilic bactericidal systems, and antibody production.

Main Results:

• Immunofan restores cell immunity, enhances neutrophilic bactericidal activity, and boosts antiviral antibody production.
• It reduces inflammatory mediators (TNF, IL-6) and activates the redox system.
• In cancer therapy, Immunofan improves antioxidant capacity and reduces treatment side effects, ensuring treatment continuity.

Conclusions:

• Immunofan demonstrates significant immunocorrective and pathogenetic therapeutic effects.
• It is effective in complex therapy for cancer, chronic infections, and opportunistic infections.
• Immunofan enhances immune response, shortens disease symptoms, and improves patient outcomes.